Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE).

Tran, Ai Phuong; Tassone, Daniel; Nossent, Johannes; Ding, Nik Sheng

Tran, Ai Phuong; Tassone, Daniel; Nossent, Johannes; Ding, Nik Sheng.

Affiliation

Tran AP; School of Medicine and Pharmacology, The University of Western Australia, Perth, Western Australia, Australia ai.tran@research.uwa.edu.au.
Tassone D; Department of Rheumatology, St John of God Murdoch, Perth, Western Australia, Australia.
Nossent J; Faculty of Medicine, Dentistry and Health Sciences, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
Ding NS; School of Medicine and Pharmacology, The University of Western Australia, Perth, Western Australia, Australia.

RMD Open ; 8(1)2022 05.

Article in En | MEDLINE | ID: mdl-35577478

Subject(s)

Antirheumatic Agents; COVID-19; Adult; Antibodies, Viral; Antibody Formation; COVID-19/prevention & control; COVID-19 Vaccines/therapeutic use; Humans; Immunoglobulin G; RNA, Viral; SARS-CoV-2; Vaccines, Synthetic; mRNA Vaccines

Key words

COVID-19; antirheumatic agents; vaccination

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antirheumatic Agents / COVID-19 Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: RMD Open Year: 2022 Document type: Article Affiliation country: Australia Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google